0.95
+0.0456(+5.04%)
Currency In USD
| Previous Close | 0.9 |
| Open | 0.92 |
| Day High | 0.96 |
| Day Low | 0.91 |
| 52-Week High | 1.69 |
| 52-Week Low | 0.7 |
| Volume | 145,604 |
| Average Volume | 552,387 |
| Market Cap | 34.82M |
| PE | -2.64 |
| EPS | -0.36 |
| Moving Average 50 Days | 1.06 |
| Moving Average 200 Days | 1.11 |
| Change | 0.05 |
If you invested $1000 in RenovoRx, Inc. (RNXT) since IPO date, it would be worth $130.85 as of December 04, 2025 at a share price of $0.95. Whereas If you bought $1000 worth of RenovoRx, Inc. (RNXT) shares 3 years ago, it would be worth $527.78 as of December 04, 2025 at a share price of $0.95.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th
GlobeNewswire Inc.
Dec 01, 2025 1:30 PM GMT
MOUNTAIN VIEW, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared dr
RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th
GlobeNewswire Inc.
Nov 19, 2025 1:30 PM GMT
MOUNTAIN VIEW, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared dr
RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD
GlobeNewswire Inc.
Nov 06, 2025 1:30 PM GMT
Company Appoints Distinguished UCLA Oncology Surgeon to SAB, Enhancing Board’s Expertise in Surgical Oncology and Translational Oncology Research Aimed at Improving Multidisciplinary Treatment StrategiesMOUNTAIN VIEW, Calif., Nov. 06, 2025 (GLOBE N